THE Food and Drug Analyst Department in the wake of information received from Heath Canada on health Hazard Evaluation conducted by both Health Canada and manufacturer Apotex has recalled APO Clindamycin Hydrochloride 150 and 300mg; batches HL 0314, HT 1470, HY 7888 and JC 7887.

According to a release the said batches of Clindamycin active raw material and certain beta-antibiotics were found to have inadequate separation of the operations during manufacturing, thus creating a great potential for cross-contamination even though this was not categorically confirmed.

The release added that although the potential for serious adverse health consequences was unconfirmed and remote Apotex is voluntarily recalling the product as a precautionary measure, due to the sensitizing nature of the potential contamination.

The department is calling on all importers, pharmacies and health car e providers to surrender the said batches of APO Clindamycin to the Food and Drug Analyst Department.